Previous studies [28,30,31,33,35,82,83,84,85,86,87] have suggested several potential biomarkers of immunotherapy in the metastatic setting, including PD-L1 expression, molecular subtyping, tumor mutation burden, gene expression subtype, and DNA damage response gene alteration; however, the reliability of predictive biomarkers remains dubious in the perioperative and metastatic settings. The gene discussed is CD274; the disease is neoplasm.